Filing identity and reporting period
Important metadata discrepancy: The request identifies Lite Strategy, Inc. and 2017 Q1, but the supplied filing is MEI Pharma, Inc. (NASDAQ: MEIP), a Form 10-Q for the quarter ended September 30, 2018 (fiscal 2019 Q1). This summary reflects the supplied filing.
MEI Pharma is a clinical-stage oncology company with four drug candidates: pracinostat, ME-401, voruciclib and ME-344. The unaudited interim financial statements are prepared under U.S. GAAP.
Financial performance and position
Amounts below are in U.S. dollars; financial statement amounts are converted from thousands to millions.
| Metric | Quarter ended Sep. 30, 2018 | Comparable 2017 period or prior balance-sheet date |
|---|---|---|
| Revenue | $0.488 million | $0.283 million |
| Operating expenses | $10.521 million | $9.170 million |
| Operating loss | $10.033 million | $8.887 million |
| Net loss | $14.542 million | $8.788 million |
| Basic and diluted loss per share | $0.21 | $0.24 |
| Cash, cash equivalents and short-term investments | $90.764 million | $102.743 million at June 30, 2018 |
| Operating cash used | $12.816 million | $6.562 million |
- Revenue was entirely research-and-development revenue under the Helsinn agreement. Related cost was $0.989 million, exceeding revenue by $0.501 million; the filing does not present a conventional gross margin.
- Research and development expense was $6.131 million, nearly unchanged year over year. General and administrative expense rose to $3.401 million from $2.488 million.
- Net loss included a $4.962 million non-cash expense from remeasurement of liability-classified warrants. Interest and dividend income was $0.454 million, compared with $0.100 million.
- Cash and investments were primarily cash and U.S. government securities. Current assets were $94.435 million and current liabilities $4.784 million; the resulting current ratio was approximately 19.7x. Accumulated deficit was $228.941 million.
- Total liabilities were $54.991 million, including a $50.207 million warrant liability. The filing does not report conventional borrowings or debt on the balance sheet.
- Operating cash use increased year over year, which management attributed primarily to working-capital changes associated with clinical development, including ME-401 Phase 2 study start-up costs. Financing activities provided $0.837 million, mainly from warrant and option exercises.
Material changes versus the prior comparable period
- Net loss widened to $14.542 million from $8.788 million, principally reflecting the warrant fair-value expense and higher operating expenses; loss per share decreased from $0.24 to $0.21 as weighted-average shares increased substantially.
- Research and development expense was broadly flat, but spending shifted: ME-401 costs rose to $2.505 million from $1.456 million, while voruciclib costs fell to $1.011 million from $2.955 million. The prior-year voruciclib expense included a $2.9 million license payment.
- General and administrative expense increased by $0.913 million, including higher share-based compensation and professional and corporate costs. Total share-based compensation rose to $1.937 million from $0.996 million.
- Cash and investments declined $11.979 million from June 30, 2018; operating cash use was nearly double the comparable quarter.
Outlook, developments and risks
- Management said the $90.8 million of cash and investments was expected to fund operations through at least fiscal 2020. The company expects operating losses and negative operating cash flows for the foreseeable future and anticipates seeking future funding through equity, licensing or strategic partnerships.
- ME-401: The company planned to begin a global randomized Phase 2 trial in relapsed or refractory follicular lymphoma by year-end 2018, aiming to support an accelerated-approval application. The filing describes this as a development plan, not an assurance of approval. In October 2018, MEI announced a cost-sharing clinical collaboration with BeiGene to test ME-401 with zanubrutinib.
- In November 2018, after quarter-end, MEI announced a Japan license for ME-401 to Kyowa Hakko Kirin, including a $10 million upfront payment, potential milestones up to $87.5 million and tiered double-digit royalties. These are subsequent-event terms, not quarter-end cash or recognized revenue.
- Pracinostat’s Phase 3 AML trial is run and primarily funded by Helsinn. MEI conducts a Phase 2 MDS study, with costs shared with Helsinn. MEI reported that an interim tolerability threshold was met and enrollment expanded to 60 patients.
- Voruciclib entered a Phase 1b dose-ranging study in August 2018. ME-344 remained in an investigator-initiated breast-cancer combination study; interim results showed a Ki-67 reduction signal, but the reported comparisons were not statistically conclusive.
- Key risks include clinical-trial failure or delay, regulatory uncertainty, dependence on collaborators and third parties, need for future financing, and potential milestone and royalty obligations. Potential Presage, S*Bio and CyDex payments were not accrued because they depend on future events. The filing reports no material change in risk factors from the 2018 annual report.
- The May 2018 private placement warrants are liability-classified and valued using significant unobservable assumptions; changes in share price and valuation inputs can materially affect reported earnings. The company also added office space in September 2018; combined remaining lease obligations were approximately $1.3 million.
Most important facts for investors to verify
- Confirm the intended company and period: the supplied document is MEI Pharma’s quarter ended September 30, 2018, not a Lite Strategy, Inc. 2017 Q1 filing.
- Track cash burn against management’s stated funding horizon, including whether development spending or working-capital needs materially change.
- Check subsequent filings for ME-401 Phase 2 initiation, trial progress and results, and the timing and receipt of the Kyowa Hakko Kirin upfront payment.
- Assess the warrant liability’s valuation and potential dilution: 16.062 million liability-classified warrants remained outstanding at September 30, 2018.
- Monitor clinical and regulatory outcomes, collaboration performance, and contingent obligations under the Presage, S*Bio and other license arrangements.